Know Cancer

forgot password

Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans

Phase 2
18 Years
Not Enrolling
Dermatofibrosarcoma Protuberans

Thank you

Trial Information

Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans

Inclusion Criteria

Inclusion criteria:

1. Patients ≥ or equal to 18 years of age.

2. Suspected or documented diagnosis of dermatofibrosarcoma protuberans (DFSP). Patients
with suspected diagnosis of DSFP must have DFSP confirmed by pathology at the local
institution prior to dispensing and the start of imatinib.

3. Patient is medically able to undergo surgical resection of the DFSP and resection of
the DFSP is recommended for clinical management of the disease.

4. Patient has at least one site of measurable (macroscopic) disease.

5. Performance status 0, 1 or 2 Eastern Cooperative Oncology Group (ECOG) (see Section

6. Adequate end organ function, defined as the following:

total bilirubin < 1.5 x institutional upper limit of normal (ULN), SGOT and SGPT <
2.5 x UNL, creatinine < 1.5 x ULN, absolute neutrophil count > 1.5 x 109/L, platelets
> 100 x 109/L.

7. Female patients of childbearing potential must have negative pregnancy test within 7
days before initiation of study drug dosing. Postmenopausal women must be amenorrheic
for at least 12 months to be considered of non-childbearing potential. Male and
female patients of reproductive potential must agree to employ an effective barrier
method of birth control throughout the study and for up to 3 months following
discontinuation of study drug.

8. Written, voluntary informed consent.

Exclusion criteria:

1. Patients who will receive radiation therapy to the site of DFSP prior to resection.

2. Patients with Grade III/IV cardiac problems as defined by the New York Heart
Association Criteria (i.e., congestive heart failure, myocardial infarction within 6
months of study).

3. Female patients who are pregnant or breast-feeding.

4. Patients who have a severe and/or uncontrolled medical disease (i.e., uncontrolled
diabetes, chronic renal disease, or active uncontrolled infection) that may worsen
because of imatinib.

5. Patients who have known chronic liver disease (i.e., chronic active hepatitis, and

6. Patients who have a known diagnosis of human immunodeficiency virus (HIV) infection.

7. Patients who have received chemotherapy within 4 weeks prior to study entry.

8. Patients who have had a major surgery within 2 weeks prior to study entry. Incisional
biopsy or partial excision of dermatofibrosarcoma protuberans to establish the
diagnosis and/or to collect pretreatment tumor tissue does not qualify as major

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and Tissue Array Studies.

Outcome Description:

To obtain matched tumor tissue samples of trial participants dermatofibrosarcoma protuberans (DFSP)for the purpose of determining whether imatinib mesylate affects autocrine/paracrine stimulated signal transduction through the platelet-derived growth factor receptor pathway in DFSP by comparing the level of phosphorylated platelet-derived growth factor receptor beta (PDGFRB) in DFSP after up to 2 weeks of treatment with imatinib to the level of phosphorylated PDGFRB pre-treatment.

Outcome Time Frame:

Prior to and after 2-weeks of imatinib therapy

Safety Issue:


Principal Investigator

Scott Schuetze, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Michigan


United States: Institutional Review Board

Study ID:




Start Date:

May 2006

Completion Date:

September 2009

Related Keywords:

  • Dermatofibrosarcoma Protuberans
  • newly diagnosed or recurrent
  • Dermatofibrosarcoma



MD Anderson Cancer Center Houston, Texas  77030-4096
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan  48109-0752
H. Lee Moffitt Cancer Center Tampa, Florida  33612
Pennsylvania Onc/Hem Assoc. Philadelphia, Pennsylvania  19106